ISSN |
1948-5182 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Prospective Study |
Article Title |
Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Satoshi Hiramine, Norihiro Furusyo, Eiichi Ogawa, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda and Jun Hayashi |
Funding Agency and Grant Number |
|
Corresponding Author |
Jun Hayashi, MD, PhD, Kyushu General Internal Medicine Center, Hara-Doi Hospital, 6-40-8 Aoba, Higashi-ku, Fukuoka 813-8588, Japan. hayashij@gim.med.kyushu-u.ac.jp
|
Key Words |
Chronic hepatitis C; Direct-acting antiviral agent; Rapid virological response; Early virological response; Response-guided treatment |
Core Tip |
Although an undetectable viral level at week 4 or 12 is a good predictor of the outcome of hepatitis C for conventional interferon therapy without direct-acting antiviral agents (DAAs); the transition of the viral level during DAA therapy has not been well documented. In this prospective multicenter study, we frequently tested 253 patients to investigate viral activity during triple therapy containing telaprevir, the first approved DAA, and found that an undetectable viral level at week 6 was the most effective predictor of disease outcome. Our findings suggest that the most predictive time point in DAA therapy is different from conventional therapy markers.
|
Publish Date |
2015-11-18 11:12 |
Citation |
Hiramine S, Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Koyanagi T, Kotoh K, Shimoda S, Hayashi J. Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. World J Hepatol 2015; 7(26): 2688-2695 |
URL |
http://www.wjgnet.com/1948-5182/full/v7/i26/2688.htm |
DOI |
http://dx.doi.org/10.4254/wjh.v7.i26.2688 |